Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1976 3
1977 1
1980 1
1981 1
1982 1
1983 4
1984 3
1985 3
1986 4
1987 7
1988 2
1989 2
1990 4
1991 2
1992 4
1993 2
1994 3
1995 3
1996 3
1997 4
1998 2
1999 6
2000 2
2001 4
2002 7
2003 5
2004 4
2005 1
2006 3
2007 3
2008 4
2009 7
2011 4
2012 2
2013 4
2014 2
2015 1
2016 2
2017 2
2018 2
2019 3
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Microinvasive carcinoma of the cervix.
Sevin BU, Nadji M, Averette HE, Hilsenbeck S, Smith D, Lampe B. Sevin BU, et al. Cancer. 1992 Oct 15;70(8):2121-8. doi: 10.1002/1097-0142(19921015)70:8<2121::aid-cncr2820700819>3.0.co;2-s. Cancer. 1992. PMID: 1394041 Review.
These data support the conclusion that MIC, defined by either the SGO or FIGO definitions, have a low risk for lymph node metastasis or recurrent carcinoma. A review of the literature indicated a recurrence rate for Stage IA2 of 4.2%. In addition to depth of invasio …
These data support the conclusion that MIC, defined by either the SGO or FIGO definitions, have a low risk for lymph node metastasis or r …
Stents in the GI tract.
Homs MY, Siersema PD. Homs MY, et al. Expert Rev Med Devices. 2007 Sep;4(5):741-52. doi: 10.1586/17434440.4.5.741. Expert Rev Med Devices. 2007. PMID: 17850208 Review.
Stents are also the treatment of choice for esophagorespiratory fistulas, for proximal malignant lesions near the upper esophageal sphincter, for recurrent carcinoma after esophagectomy or gastrectomy and for sealing traumatic or iatrogenic nonmalignant ruptures, su …
Stents are also the treatment of choice for esophagorespiratory fistulas, for proximal malignant lesions near the upper esophageal sphincter …
Salvage surgery for recurrent carcinoma of the oral cavity: assessment of prognostic factors.
Nandy K, Rai S, Bhatt S, Puj K, Rathod P, Gangopadhyay A. Nandy K, et al. Int J Oral Maxillofac Surg. 2022 May;51(5):602-611. doi: 10.1016/j.ijom.2021.07.020. Epub 2021 Aug 19. Int J Oral Maxillofac Surg. 2022. PMID: 34419287
Prognostic factors need to be assessed to select patients for salvage surgery who would benefit the most. This was a single-centre retrospective observational study conducted between 2015 and 2018. A total of 168 patients with recurrent oral cavity carcinoma who underwent …
Prognostic factors need to be assessed to select patients for salvage surgery who would benefit the most. This was a single-centre retrospec …
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
Jackson CG, Moore KN, Cantrell L, Erickson BK, Duska LR, Richardson DL, Landrum LM, Holman LL, Walker JL, Mannel RS, Moxley KM, Queimado L, Cohoon A, Ding K, Dockery LE. Jackson CG, et al. Gynecol Oncol. 2022 Jul;166(1):44-49. doi: 10.1016/j.ygyno.2022.04.016. Epub 2022 Apr 28. Gynecol Oncol. 2022. PMID: 35491267 Free PMC article. Clinical Trial.
Patients with ARID1A mutations displayed a better response rate (33%) and 6-month progression free survival (PFS6) rate (67%) than the entire study population. Observed toxicity was similar to that of previous studies with bevacizumab and rucaparib. ...However, patients wi …
Patients with ARID1A mutations displayed a better response rate (33%) and 6-month progression free survival (PFS6) rate (67%) than the entir …
Limb salvage surgery with vascular reconstruction.
Leggon RE, Huber TS, Scarborough MT. Leggon RE, et al. Clin Orthop Relat Res. 2001 Jun;(387):207-16. doi: 10.1097/00003086-200106000-00028. Clin Orthop Relat Res. 2001. PMID: 11400886 Review.
The tumor stage included one Stage IB, 12 Stage IIB, two Stage IIIB sarcomas, and one multiply recurrent carcinoma. The largest average tumor dimension was 9.5 cm, and the length of grafting was 14 cm. ...Results observed from this series and data gathered fr …
The tumor stage included one Stage IB, 12 Stage IIB, two Stage IIIB sarcomas, and one multiply recurrent carcinoma. The larges …
Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix.
Gebbia V, Caruso M, Testa A, Mauceri G, Borsellino N, Chiarenza M, Pizzardi N, Palmeri S. Gebbia V, et al. Oncology. 2002;63(1):31-7. doi: 10.1159/000065717. Oncology. 2002. PMID: 12187068 Clinical Trial.
Grade 3 vomiting was recorded in 9 patients (21%), and mild mucositis in 14% of patients. Grade 3 neutropenia was observed in 21% of patients, while grade 4 in 12% of cases with neutropenic fever was seen in 4 cases. ...CONCLUSIONS: The results achieved in this trial sugge …
Grade 3 vomiting was recorded in 9 patients (21%), and mild mucositis in 14% of patients. Grade 3 neutropenia was observed in 21% of …
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF, Farinas-Madrid L, Oaknin A. Grau JF, et al. Int J Gynecol Cancer. 2020 Jan;30(1):139-143. doi: 10.1136/ijgc-2019-000880. Epub 2019 Oct 23. Int J Gynecol Cancer. 2020. PMID: 31645423 Clinical Trial.
Women are not eligible if they have received prior systemic anti-cancer therapy for metastatic or persistent/recurrent disease or they have disease involving the bladder or rectum at the screening/baseline pelvic magnetic resonance imaging. PRIMARY ENDPOINT: Overall survival, def …
Women are not eligible if they have received prior systemic anti-cancer therapy for metastatic or persistent/recurrent disease or they have …
The accuracy and safety of CT-guided iodine-125 seed implantation assisted by 3D non-coplanar template for retroperitoneal recurrent carcinoma.
Jiang W, Jiang P, Wei S, Jiang Y, Ji Z, Sun H, Fan J, Li W, Shao Y, Wang J. Jiang W, et al. World J Surg Oncol. 2020 Nov 25;18(1):307. doi: 10.1186/s12957-020-02087-0. World J Surg Oncol. 2020. PMID: 33239023 Free PMC article.
The other parameters showed no differences among preoperative plan, intraoperative plan, and postoperative plan. The perioperative complications were observed in four patients, including three patients of grade 1 and one patient of grade 2. No grade 3 side effects were …
The other parameters showed no differences among preoperative plan, intraoperative plan, and postoperative plan. The perioperative complicat …
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA; Hellenic Co-operative Oncology Group. Papadimitriou CA, et al. Gynecol Oncol. 2008 Jul;110(1):87-92. doi: 10.1016/j.ygyno.2008.03.004. Epub 2008 May 2. Gynecol Oncol. 2008. PMID: 18455782 Clinical Trial.
We administered the combination of paclitaxel, epirubicin and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity. ...CONCLUSIONS: The combination of paclitaxel, epirubicin and carbopl …
We administered the combination of paclitaxel, epirubicin and carboplatin to patients with metastatic or recurrent carcinoma o …
Therapy of isolated locoregional recurrent carcinoma of the breast.
Gabriel L, Schmidt M, Juhasz-Böss S, Melchior P, von Heesen A, Schmidt G, Kranzhöfer N, Solomayer EF, Juhasz-Böss I, Breitbach GP. Gabriel L, et al. Arch Gynecol Obstet. 2019 Aug;300(2):365-376. doi: 10.1007/s00404-019-05220-x. Epub 2019 Jun 20. Arch Gynecol Obstet. 2019. PMID: 31222400
RESULTS: In total, we collected data of 93 patients with locally recurrent breast cancer and observed a 72.6% questionnaire response rate. Average timeline accounted for 99 months between primary diagnosis and local recurrence; average age of patients at diagnosis of local …
RESULTS: In total, we collected data of 93 patients with locally recurrent breast cancer and observed a 72.6% questionnaire response …
128 results